# Agios Pharmaceuticals Inc. (AGIO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.66B  
**Price:** $28.72 (-0.55%)

> Agios Pharmaceuticals Inc. is a biopharmaceutical company specializing in cellular metabolism to develop differentiated medicines for rare diseases, with a particular emphasis on classical hematology. The company focuses on creating potentially transformative small-molecule therapies targeting unmet medical needs in hemolytic anemias and related conditions. Its lead product, Pyrukynd (mitapivat), serves as an activator of both wild-type and mutant pyruvate kinase enzymes, addressing hemolytic anemias. The pipeline also features other candidates such as Tebapivat, a PK activator under development for MDS-associated anemia and sickle cell disease, along with AG-181, a PAH stabilizer, and AG-236. Agios Pharmaceuticals Inc. plays a vital role in advancing treatments for genetically defined rare diseases, leveraging expertise in metabolic pathways to innovate oral therapies that could alter disease progression for patients lacking effective options. Founded in 2007 and headquartered in Cambridge, Massachusetts, the company remains dedicated to this focused therapeutic area in the biopharmaceutical sector.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $54M | $48M | -$472M | -$413M | — |
| 2024 | $36M | $32M | -$426M | $674M | — |
| 2023 | $27M | $24M | -$391M | -$352M | — |
| 2022 | $14M | $13M | -$389M | -$232M | — |
| 2021 | — | — | -$378M | $1.60B | — |
| 2020 | — | — | -$336M | -$327M | — |
| 2019 | $118M | $117M | -$316M | -$411M | — |
| 2018 | $94M | $93M | -$362M | -$346M | — |
| 2017 | $43M | $43M | -$321M | -$315M | — |
| 2016 | $70M | $70M | -$201M | -$198M | — |
| 2015 | $59M | — | -$119M | -$118M | — |
| 2014 | $65M | — | -$54M | -$54M | — |
| 2013 | $26M | — | -$39M | -$39M | — |
| 2012 | $25M | — | -$23M | -$20M | — |
| 2011 | $22M | — | -$17M | -$24M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.30B | $104M | $1.19B | $89M | — |
| 2024 | $1.66B | $122M | $1.54B | $76M | — |
| 2023 | $937M | $126M | $811M | $88M | — |
| 2022 | $1.24B | $138M | $1.10B | $139M | — |
| 2021 | $1.44B | $146M | $1.29B | $203M | — |
| 2020 | $853M | $453M | $400M | $127M | — |
| 2019 | $891M | $250M | $641M | $81M | — |
| 2018 | $858M | $171M | $688M | $71M | — |
| 2017 | $614M | $239M | $376M | $103M | — |
| 2016 | $619M | $261M | $359M | $161M | — |
| 2015 | $420M | — | $345M | $72M | — |
| 2014 | $492M | — | $424M | $14M | — |
| 2013 | $201M | — | $131M | $72M | — |
| 2012 | $137M | — | -$72M | $91M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$373M | $4M | -$377M |
| 2024 | -$390M | $2M | -$392M |
| 2023 | -$296M | $999,000 | -$297M |
| 2022 | -$309M | $5M | -$314M |
| 2021 | -$407M | $6M | -$413M |
| 2020 | -$291M | $14M | -$305M |
| 2019 | -$371M | $12M | -$383M |
| 2018 | -$304M | $7M | -$311M |
| 2017 | -$285M | $5M | -$290M |
| 2016 | $39M | $10M | $29M |
| 2015 | -$77M | $20M | -$97M |
| 2013 | -$56M | $1M | -$58M |
| 2012 | -$50M | $1M | -$51M |
| 2011 | -$15M | $2M | -$17M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AGIO)